
Bausch Health Companies Inc. – NYSE:BHC
Bausch Health Companies stock price today
Bausch Health Companies stock price monthly change
Bausch Health Companies stock price quarterly change
Bausch Health Companies stock price yearly change
Bausch Health Companies key metrics
Market Cap | 2.74B |
Enterprise value | 22.96B |
P/E | -12.1 |
EV/Sales | 2.82 |
EV/EBITDA | 8.45 |
Price/Sales | 0.34 |
Price/Book | -3.99 |
PEG ratio | -0.15 |
EPS | -0.04 |
Revenue | 8.95B |
EBITDA | -1.07B |
Income | -20.71M |
Revenue Q/Q | 10.25% |
Revenue Y/Y | 9.89% |
Profit margin | -2.77% |
Oper. margin | 17.12% |
Gross margin | 70.9% |
EBIT margin | 17.12% |
EBITDA margin | -12.04% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBausch Health Companies stock price history
Bausch Health Companies stock forecast
Bausch Health Companies financial statements
$10
Potential upside: 27.56%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 2.16B | 26M | 1.2% |
---|---|---|---|
Sep 2023 | 2.23B | -378M | -16.89% |
Dec 2023 | 2.40B | 395M | 16.4% |
Mar 2024 | 2.14B | -63.71M | -2.97% |
Jun 2023 | 33796830630 | 33.43B | 98.94% |
---|---|---|---|
Sep 2023 | 27064000000 | 27.29B | 100.87% |
Dec 2023 | 27350000000 | 27.43B | 100.3% |
Mar 2024 | 26885256733 | 27.05B | 100.65% |
Jun 2023 | 268.77M | -37.61M | -120M |
---|---|---|---|
Sep 2023 | 282M | -1.88B | 1.81B |
Dec 2023 | 390M | -148M | -79M |
Mar 2024 | 206.07M | -72.67M | -334.49M |
Bausch Health Companies alternative data
Sep 2023 | 19,900 |
---|---|
Oct 2023 | 19,900 |
Nov 2023 | 19,900 |
Dec 2023 | 19,900 |
Jan 2024 | 19,900 |
Feb 2024 | 19,900 |
Apr 2024 | 20,270 |
May 2024 | 20,270 |
Jun 2024 | 20,270 |
Jul 2024 | 20,270 |
Bausch Health Companies other data
Period | Buy | Sel |
---|---|---|
Mar 2024 | 0 | 6313 |
Sep 2024 | 0 | 13370 |
Dec 2024 | 0 | 440 |
Quarter | Transcript |
---|---|
Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Repricing Potential Driven By Deleveraging
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity
Bausch + Lomb Corporation: Spin-Off Ready To Fly Troubled Nest And Find Upside
DaVita: Continued Economic Hurdles, Market Expectations May Be Correct
Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Bausch Health: Bullish On Long-Term Prospects, Awaiting Subsiding Headwinds
Tracking Carl Icahn's Portfolio - Q4 2022 Update
Bausch Health: Full Bausch + Lomb Spin-Off Finally Seems Close
Bausch + Lomb: Brent Saunders Return Bodes Well For Shareholders
-
What's the price of Bausch Health Companies stock today?
One share of Bausch Health Companies stock can currently be purchased for approximately $7.84.
-
When is Bausch Health Companies's next earnings date?
Unfortunately, Bausch Health Companies's (BHC) next earnings date is currently unknown.
-
Does Bausch Health Companies pay dividends?
No, Bausch Health Companies does not pay dividends.
-
How much money does Bausch Health Companies make?
Bausch Health Companies has a market capitalization of 2.74B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 7.79% to 8.76B US dollars.
-
What is Bausch Health Companies's stock symbol?
Bausch Health Companies Inc. is traded on the NYSE under the ticker symbol "BHC".
-
What is Bausch Health Companies's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Bausch Health Companies?
Shares of Bausch Health Companies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bausch Health Companies's key executives?
Bausch Health Companies's management team includes the following people:
- Mr. Joseph C. Papa Chief Executive Officer & Chairman(age: 69, pay: $3,740,000)
- Mr. Thomas J. Appio Pres & Co-Head Bausch + Lomb/International(age: 63, pay: $2,160,000)
- Mr. Paul S. Herendeen Executive Vice President and Advisor to Chairman & Chief Executive Officer(age: 69, pay: $2,100,000)
- Ms. Christina M. Ackermann Executive Vice President, Gen. Counsel & Head of Commercial Operations(age: 60, pay: $1,310,000)
-
How many employees does Bausch Health Companies have?
As Jul 2024, Bausch Health Companies employs 20,270 workers.
-
When Bausch Health Companies went public?
Bausch Health Companies Inc. is publicly traded company for more then 31 years since IPO on 29 Mar 1994.
-
What is Bausch Health Companies's official website?
The official website for Bausch Health Companies is bauschhealth.com.
-
Where are Bausch Health Companies's headquarters?
Bausch Health Companies is headquartered at 2150 St. ElzEar Boulevard West, Laval, QC.
-
How can i contact Bausch Health Companies?
Bausch Health Companies's mailing address is 2150 St. ElzEar Boulevard West, Laval, QC and company can be reached via phone at +1 514 744 6792.
-
What is Bausch Health Companies stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Bausch Health Companies in the last 12 months, the avarage price target is $10. The average price target represents a 27.56% change from the last price of $7.84.
Bausch Health Companies company profile:

Bausch Health Companies Inc.
bauschhealth.comNYSE
20,270
Drug Manufacturers - Specialty & Generic
Healthcare
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Laval, QC H7L 4A8
CIK: 0000885590
ISIN: CA0717341071
CUSIP: 071734107